MyJournals.org - Science - [ASAP] Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy (Molecular Pharmaceutics)
Key Highlights
Nominated EB-373 as lead development candidate for the treatment of anxiety disorders
EB-373 is a next generation proprietary psilocin prodrug selected from Enveric’s. | April 3, 2023
Nextleaf Solutions Ltd.: Nextleaf Solutions Granted Patent for CBD Prodrug and Prepares for Pharmaceutical Participation
CSE: OILS) (
OILS , or the
Company ), the world s most innovative cannabis extractor, announced today that the Canadian Intellectual Property Office has granted the Company a patent for the acetylation of cannabinoids. More specifically, the patent covers a process for acetylating cannabidiol ( CBD ), and subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=SCVOJPYFDAI
The Company owns 12 issued U.S. patents and 70 issued patents globally for the extraction, purification, and delivery of cannabinoids - representing the 2nd largest patent portfolio among all cannabis companies.